Genomic Vision Will Publish Its Annual Results on May 21, 2020
30 Abril 2020 - 02:16PM
Business Wire
Regulatory News:
Genomic Vision (FR0011799907 – GV) (Paris:GV), a
biotechnology company that develops tools and services dedicated to
the analysis and control of changes in the genome, today announces
the postponement of the publication of its 2019 full-year results
until May 21, after the close of trading.
Due to recent developments within the Management Board and the
Supervisory Board and given the constraints imposed by the current
context, the meeting of the Supervisory Board to close the annual
financial statements has been postponed to May 21, 2020.
Consequently, the publication of the annual results will take place
on that day after the close of the markets and will also include
the quarterly information as of March 31, 2020.
***
ABOUT GENOMIC VISION
GENOMIC VISION is a biotechnology company developing products
and services dedicated to the analysis (structural and functional)
of genome modifications as well as to the quality and safety
control of these modifications, in particular in genome editing
technologies and biomanufacturing processes. Genomic Vision
proprietary tools, based on DNA combing technology and artificial
intelligence, provide robust quantitative measurements needed to
high confidence characterization of DNA alteration in the genome.
These tools are mainly used for monitoring DNA replication in
cancerous cell, for early cancer detection and the diagnosis of
genetic diseases. Based near Paris, in Bagneux, the Company has
approximately 30 employees. GENOMIC VISION is a public listed
company listed in compartment C of Euronext’s regulated market in
Paris (Euronext: GV – ISIN: FR0011799907).
For further information, please visit www.genomicvision.com
Member of the CAC® Mid & Small and CAC® All-Tradable
indexes
FORWARD LOOKING STATEMENT
This press release contains implicitly or explicitly certain
forward-looking statements concerning Genomic Vision and its
business. Such forward-looking statements are based on assumptions
that Genomic Vision considers to be reasonable. However, there can
be no assurance that such forward-looking statements will be
verified, which statements are subject to numerous risks, including
the risks set forth in the “Risk Factors” section of the reference
document dated March 29, 2019 filed with the AMF under reference
number R19-004, available on the web site of Genomic Vision
(www.genomicvision.com) and to the development of economic
conditions, financial markets and the markets in which Genomic
Vision operates. The forward-looking statements contained in this
press release are also subject to risks not yet known to Genomic
Vision or not currently considered material by Genomic Vision. The
occurrence of all or part of such risks could cause actual results,
financial conditions, performance or achievements of Genomic Vision
to be materially different from such forward-looking
statements.
This press release and the information contained herein do not
constitute and should not be construed as an offer or an invitation
to sell or subscribe, or the solicitation of any order or
invitation to purchase or subscribe for Genomic Vision shares in
any country. The distribution of this press release in certain
countries may be a breach of applicable laws. The persons in
possession of this press release must inquire about any local
restrictions and comply with these restrictions.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200430005794/en/
Genomic Vision Dominique Rémy-Renou CEO Tel.: +33 1 49 08
07 51 investisseurs@genomicvision.com
Ulysse Communication Press Relations Bruno Arabian Tel.:
+33 1 42 68 29 70 barabian@ulysse-communication.com
NewCap Investor Relations & Strategic Communications
Tel.: +33 1 44 71 94 94 gv@newcap.eu
Genomic Vision (EU:GV)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
Genomic Vision (EU:GV)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024